Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunic, Inc. (IMUX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer, Immunic uses filings such as Forms 10-K, 10-Q, and 8-K to report on its financial condition, clinical development progress, capital structure, and material corporate events.
Current reports on Form 8-K are particularly relevant for tracking Immunic’s milestones. Recent 8-K filings reference press releases on quarterly financial results and corporate updates, including spending on research and development for vidofludimus calcium (IMU-838) and other programs, as well as financings such as registered direct offerings and underwritten public offerings. Other 8-Ks describe presentation of new multiple sclerosis data at major scientific meetings and provide details on items like stock appreciation rights grants and Nasdaq listing notices regarding minimum bid price requirements.
Investors can also use SEC filings to monitor liquidity and risk disclosures, where Immunic discusses its cash and cash equivalents, the need to raise additional capital to fund operations, and the implications of financing structures. Filings may further elaborate on the company’s intellectual property strategy for vidofludimus calcium and other pipeline assets, complementing information in press releases.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points in accessible language, helping readers quickly understand the significance of lengthy filings. Real-time updates from EDGAR ensure that new IMUX filings, including 10-Q and 10-K reports and any Form 4 insider transaction disclosures when available, are added promptly so users can review changes in ownership, compensation-related grants, and other governance matters alongside Immunic’s clinical and financial reporting.
Immunic CEO Daniel Vitt filed an amended Form 4 on June 28, 2025, correcting a previously filed Form 4 from June 6, 2025. The amendment addresses two significant transactions:
- Stock Purchase: Acquired 15,000 shares of common stock at $0.77 per share on June 4, 2025, bringing direct ownership to 29,000 shares
- Stock Option Grant: Received 1,558,000 stock options on June 5, 2025, with an exercise price of $0.7729, expiring June 5, 2035
The options vest 25% after one year, with remaining shares vesting monthly over 36 months. Vitt also maintains indirect ownership of 362,877 shares through Listrax UG, where he serves as Managing Director. The amendment specifically corrects an administrative error regarding the number of stock options granted in the original filing.
Immunic has filed a Form 4/A (amended insider trading report) for Executive Chairman and Director Duane Nash, correcting a previously filed Form 4 from June 9, 2025. The amendment addresses an administrative error in the reported number of stock options granted.
Key details of the transaction:
- Transaction Date: June 5, 2025
- Granted 570,000 stock options to purchase common stock
- Exercise price: $0.7729 per share
- Options expire on June 5, 2035
- Vesting schedule: Monthly increments over one year from grant date
This filing represents a significant equity compensation grant to a senior executive, with the options having a 10-year exercise period. The relatively low exercise price and substantial option quantity suggests a strong alignment of management interests with shareholders.
This Form 4/A amends a previously filed Form 4 for Andreas Muehler, Chief Medical Officer of Immunic (IMUX), correcting an administrative error in reported stock option grants.
Key details of the amended filing:
- Transaction Date: June 5, 2025
- Grant of 598,500 stock options at exercise price of $0.7729 per share
- Options expire on June 5, 2035
- Vesting Schedule: 25% after first year, remaining 75% monthly over next 36 months
The amendment was necessary to correct the number of stock options granted, which was incorrectly reported in the original Form 4 filed on June 9, 2025. The options represent a significant equity compensation package for the CMO, with a ten-year exercise window.